Abivax shares surged nearly 6.0% to €124.5 on Euronext Paris following the company’s disclosure that underwriters had fully exercised their option to buy an additional 960,000 American Depositary Shares (ADSs). That exercise raised the total gross proceeds from the offering to $920 million (€807 million).
The additional ADSs represent 15% of the ADSs originally sold in the deal. The full exercise of the overallotment - commonly known as a greenshoe - was announced at 8:00 a.m. CEST and capped a capital raise that had already been increased once. On July 1, 2026, Abivax priced 6,400,000 ADSs at $125.00 per ADS, after boosting the offering from a previously announced $600 million.
Market participants viewed the underwriters’ full exercise as a tangible sign of institutional support. The offering was described as highly oversubscribed prior to the greenshoe, and the expected gross proceeds before the underwriters’ option were projected to extend Abivax’s cash runway into the second quarter of 2029. That runway was expected to support both potential commercialization of obefazimod and continued clinical development.
Including the proceeds from the greenshoe lifts the total to $920 million, a level the company said materially strengthens its balance sheet. On the analyst front, Jefferies raised its rating on Abivax to Buy from Hold and increased its price target to $158 from $108.
The trading environment outside of Abivax was largely neutral and did not drive the share move. The CAC 40 was trading around 8,373, up approximately 0.07%, while U.S. indices were modestly negative. Those broader market conditions underscore that Abivax’s outsized gain was driven by company-specific developments rather than macro market tailwinds.
The pricing of the offering at $125.00 per ADS was set equal to the volume-weighted average price (VWAP) of Abivax ordinary shares on Euronext Paris over the three prior trading sessions, plus a premium of 2.39%. That pricing framework helped anchor investor expectations around the current price level.
Analysts and market observers pointed to a cluster of factors behind the rally: the full greenshoe exercise, the oversubscription of the capital raise, the Jefferies upgrade, and the bolstered financial runway into 2029. Abivax also remains on schedule to submit a new drug application (NDA) to the U.S. Food and Drug Administration for obefazimod in the fourth quarter of 2026. The company has been widely viewed as a potential acquisition target before a commercial launch.
With institutional demand validated by the underwriters’ complete exercise of their option, market sentiment toward Abivax has shifted more firmly to the upside. Investors reacted to the enlarged cash cushion and the signaling value of the greenshoe in combination with the analyst upgrade.
Data points from the disclosure
- Share price move - nearly 6.0% to €124.5 on Euronext Paris.
- Additional ADSs purchased by underwriters - 960,000 (15% of initial ADSs sold).
- Total gross proceeds after greenshoe - $920 million (€807 million).
- ADS pricing - $125.00 per ADS, equal to three-session VWAP plus a 2.39% premium.
- Original priced ADSs - 6,400,000 on July 1, 2026; offering had been increased from $600 million.
- Analyst action - Jefferies upgraded to Buy from Hold; price target raised to $158 from $108.
- Projected cash runway prior to greenshoe - into Q2 2029 to support potential commercialization of obefazimod and continued clinical work.
The combination of a fully exercised greenshoe, an upsized and oversubscribed offering, and a prominent analyst upgrade produced a company-specific catalyst that drove the share rally. While broader indices were mixed or neutral, the financing outcome and subsequent validation of institutional demand were the proximate causes of the price move.
Investors will continue to monitor Abivax’s timeline toward its planned NDA submission for obefazimod in Q4 2026 and any further signs of potential strategic interest ahead of a commercial launch.